RECRUITINGOBSERVATIONAL
HO-1/CREB3 Modulates Golgi Stress in Patients With Sepsis
Study on the Mechanism of Endotoxic Acute Lung Injury-induced Golgi Stress Based on Regulating HO-1/CREB3
About This Trial
This study was an ambispective observational cohort study that included sepsis patients hospitalized in the Intensive care unit (ICU) of the Nankai Hospital. All patients met the consensus criteria of sepsis-3. The purpose of this study is to investigate the valuable biomarkers for the severity of sepsis and predictors of 30-day mortality for patients with sepsis.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Males or females over the age of 18;
2. Sepsis was diagnosed within 48h which meets SPESIS 3 criteria;
3. Capable of understanding the purpose and risk of the study;
4. Patients or proxy must give written willing to sign a consent form before any assessment is performed.
Who Should NOT Join This Trial:
1. Pregnancy, lactation or perinatal period;
2. Breast carcinoma;
3. HIV seropositive or Syphilis seropositive;
4. Any clinical-relevant condition that might affect study participation and/or study results;
5. Participation in any other intervention trial;
6. Unwillingness or inability to following the study protocol in the investigators opinion.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Males or females over the age of 18;
2. Sepsis was diagnosed within 48h which meets SPESIS 3 criteria;
3. Capable of understanding the purpose and risk of the study;
4. Patients or proxy must give written informed consent before any assessment is performed.
Exclusion Criteria:
1. Pregnancy, lactation or perinatal period;
2. Breast carcinoma;
3. HIV seropositive or Syphilis seropositive;
4. Any clinical-relevant condition that might affect study participation and/or study results;
5. Participation in any other intervention trial;
6. Unwillingness or inability to following the study protocol in the investigators opinion.
Treatments Being Tested
OTHER
nothing
disease
Locations (1)
Tianjin Nankai Hospital
Tianjin, Tianjin Municipality, China